Search results
Results from the WOW.Com Content Network
Interferon beta-1a (also interferon beta 1-alpha) is a cytokine in the interferon family used to treat multiple sclerosis (MS). [5] It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. [6] Some research indicates that interferon injections may result in an 18–38% reduction in the rate of MS relapses. [7]
Multiple sclerosis can cause a variety of symptoms including changes in sensation (hypoesthesia), muscle weakness, abnormal muscle spasms, impaired movement, difficulties with coordination and balance, problems in speech (known as dysarthria) or swallowing , visual problems (nystagmus, optic neuritis, or diplopia), fatigue and acute or chronic ...
The price of a new drug (in most cases) is limited so that the cost of therapy with the new drug is in the range of the costs of therapy with existing drugs in the same therapeutic class. The price of a breakthrough drug is limited to the median of its prices in France, Germany, Italy, Sweden, Switzerland, Britain, and the United States.
An online version is available, with all drug listings available to view for free. Concise drug monographs form the core of MIMS; these include safety information, details of the active ingredient, presentation, price, indication, dosage and manufacturer. In addition, the book includes drug comparison tables, and summaries of clinical guidance.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
In February 2016, the US Food and Drug Administration (FDA) granted breakthrough therapy designation for primary progressive multiple sclerosis. [21] In March 2017, the FDA approved ocrelizumab for relapsing-remitting and primary-progressive multiple sclerosis. It is the first FDA-approved treatment for the primary progressive form.
Upgrade to a faster, more secure version of a supported browser. It's free and it only takes a few moments:
Makers of the new Alzheimer's drug, Leqembi, say their twice-monthly infusion could be available in injection form at pharmacies by early 2025 — if all goes well in ongoing trials and the ...